Blackstone puts $250M into Anagram to tackle cystic fibrosis complication

Blackstone Life Sciences is putting $250 million to work on a little-known biotech seeking to drastically reduce the number of pills many cystic fibrosis patients have to take each day.

Raccontata daendpoints.news